Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$0.0 - $2.16 $0 - $809,529
-374,782 Reduced 92.35%
31,037 $67,000
Q2 2023

Aug 03, 2023

BUY
$1.4 - $1.95 $543,537 - $757,069
388,241 Added 2208.68%
405,819 $735,000
Q1 2023

May 04, 2023

BUY
$1.21 - $2.22 $10,114 - $18,556
8,359 Added 90.67%
17,578 $23,000
Q4 2022

Feb 13, 2023

BUY
$0.85 - $1.69 $6,123 - $12,174
7,204 Added 357.52%
9,219 $15,000
Q3 2022

Nov 03, 2022

SELL
$2.14 - $3.7 $84,611 - $146,290
-39,538 Reduced 95.15%
2,015 $4,000
Q2 2022

Aug 12, 2022

SELL
$2.84 - $8.57 $3,541 - $10,686
-1,247 Reduced 2.91%
41,553 $127,000
Q1 2022

May 16, 2022

BUY
$5.64 - $15.64 $241,392 - $669,392
42,800 New
42,800 $309,000

Others Institutions Holding PRDS

About PARDES BIOSCIENCES, INC.


  • Ticker PRDS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,320,900
  • Description
  • Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...
More about PRDS
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.